It was reported that, for the combined treatment of an HDAC inhibitor and DOX, better anticancer effects could be obtained by blocking DNA repair and BCR-ABL-driven double strand break (DSB) repair mechanisms in animal models of leukemia [27]. The gene discussed is ABL1; the disease is leukemia.